Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiloial Forte is a preservative-free, lubricating, and hydrating ophthalmic solution developed by Farmigea. It is formulated with a synergistic combination of high molecular weight hyaluronic acid (obtained via biotechnological synthesis) and TS-polysaccharide (tamarind seed polysaccharide, extracted from the seeds of Tamarindus indica). Hyaluronic acid acts as a mucomimetic lubricant with high water-binding capacity, stabilizing the tear film and providing long-lasting hydration. TS-polysaccharide forms a protective film on the ocular surface, aiding in the restoration of the physiological balance of the tear film and protecting the corneal-conjunctival surface. Xiloial Forte is approved and marketed as a CE medical device for the relief of dry eye syndrome and ocular irritation caused by environmental factors (wind, sun, smoke, dry air), visual stress (prolonged screen use), or mechanical factors (contact lens wear, ocular surgery).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiloial Forte.